dendritic cell

(redirected from Plasmacytoid dendritic cell)
Also found in: Medical, Encyclopedia.

dendritic cell

n.
Any of various white blood cells that have long projections from the cell body and function in the immune response by taking in and processing antigens and presenting them to T cells in lymph nodes, thus activating the T cells. Immature dendritic cells are found chiefly in skin and mucosal surfaces.
Translations
célula dendrítica
cellula dendritica
References in periodicals archive ?
Began dosing patients in the Companys Phase 1 clinical trial of IMGN632, a CD123-targeting ADC integrating a potent DNA-alkylating payload intended to treat a range of hematological malignancies, including AML and blastic plasmacytoid dendritic cell neoplasm (BPDCN); and
s (NASDAQ: IMGN) investigational new drug application for IMGN632 in patients with CD123-positive hematological malignancies, including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), the company said.
CD123, the plasmacytoid dendritic cell phenotypic marker is abundant in leprosy type 1 reaction.
2012) Constitutive plasmacytoid dendritic cell migration to the splenic white pulp is cooperatively regulated by CCR7- and CXCR4-mediated signaling.
Dendritic cells (DCs) are the most important antigenpresenting cells, and are divided into myeloid dendritic cells (mDC) and plasmacytoid dendritic cell (pDC).
Patients with blastic plasmacytoid dendritic cell neoplasms, previously known as blastic NK-cell tumors or [CD4.
Gilliet M, Conrad C, Geiges M, et al: Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.
National Library of Medicine) with the following keyword "blastic plasmacytoid dendritic cell neoplasm".
It was reported yesterday that the collaboration is aimed at accelerating the development of SL-401 for the treatment of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm, a rare haematological disorder with both leukemic and lymphomatous characteristics.
Food and Drug Administration (FDA) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy for which there is no effective treatment.
Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary infection.